Covid Vaccine From Germany's CureVac Just 48% Effective

CureVac said its jab, known as CVnCoV, did slightly better among people aged 18 to 60 than among older ages, with efficacy climbing to 53 percent.

Germany's CureVac announced Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech and Moderna. The outcome had been expected after poor interim results were released earlier this month. The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across different age groups. The Covid vaccines developed by German rival BioNTech/Pfizer and US firm Moderna were both approved some 18 months ago after showing around 95 percent efficacy.